Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190763 | 0.92 | CNR1 (0.85) | CNR1CNR2 | |
| SCHEMBL675014 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5041587 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5038475 | 0.90 | CNR1 (0.98) | CNR1CNR2 | |
| SCHEMBL5909537 | 0.88 | CNR1 (0.78) | CNR1CNR2 | |
| SCHEMBL6176509 | 0.87 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL5036931 | 0.86 | CNR1 (0.89) | CNR1CNR2 | |
| SCHEMBL5043843 | 0.86 | CNR1 (0.89) | CNR1CNR2 | |
| SCHEMBL762420 | 0.83 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL17645417 | 0.81 | CNR1 (0.67) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058264-B2 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1807063-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | ASTRAZENECA A B (SE) | 2006-06-29 | — | — | US | claimed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| WO-2006045799-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| EP-1592403-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE THIAZOLE DERIVATIVE AND EXCIPIENTS LIKE MIDDLE CHAIN TRIGLYCERIDES | AstraZeneca AB (SE) | 2005-11-09 | — | — | EP | claimed |
| EP-1581214-A1 | 4,5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | Astrazeneca AB (SE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004069226-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE THIAZOLE DERIVATIVE AND EXCIPIENTS LIKE MIDDLE CHAIN TRIGLYCERIDES | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004058255-A1 | 4, 5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | claimed |
| US-8058264-B2 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-7342032-B2 | Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity | SOLVAY PHARMACEUTICALS, INC. (NL) | 2008-03-11 | — | — | US | disclosed |
| EP-1807063-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | ASTRAZENECA A B (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| EP-1492779-A1 | THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2005-01-05 | — | — | EP | disclosed |
| US-20040266841-A1 | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | ABBVIE B.V. (NL) | 2004-12-30 | — | — | US | disclosed |
| WO-2004069226-A1 | AQUEOUS DISPERSION COMPRISING STABLE NANOPARTICLES OF A WATER-INSOLUBLE THIAZOLE DERIVATIVE AND EXCIPIENTS LIKE MIDDLE CHAIN TRIGLYCERIDES | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004058255-A1 | 4, 5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003078413-A1 | THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266841-A1 | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | CNR1, CNR2, CCKAR | CNR1 1/4885CNR2 2/4885 |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885 |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | CNR1, CNR2, NPY4R | CNR1 1/4885CNR2 2/4885 |
| US-20060141043-A1 | Aqueous dispersion comprising stable nanoparticles of a water-insoluble thiazole derivative and excipients like middle chain triglycerides | CETP, LIPC, LIPA | CNR1 4668/4885CNR2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.